Evidence map›Paper›PMID 24848744›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2014

Avidity-controlled hydrogels for injectable co-delivery of induced pluripotent stem cell-derived endothelial cells and growth factors.

Widya Mulyasasmita, Lei Cai, Ruby E Dewi, Arshi Jha, Sabrina D Ullmann, Richard H Luong, Ngan F Huang, Sarah C Heilshorn

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 90 citations in OpenAlex.

  1. Article
  2. Article
  3. Biomimetic fabricated tubular graftBioactive materials · 2025
    Article
  4. Review
  5. Injectable Biomimetic Gels for Biomedical Applications.Biomimetics (Basel, Switzerland) · 2024
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Injectable Hydrogel-Based Nanocomposites for Cardiovascular Diseases.Frontiers in bioengineering and biotechnology · 2020
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Widya MulyasasmitaDepartment of Bioengineering, Stanford University, Stanford, CA, USA.
Lei CaiDepartment of Materials Science and Engineering, Stanford University, Stanford, CA, USA; Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Ruby E DewiDepartment of Materials Science and Engineering, Stanford University, Stanford, CA, USA.
Arshi JhaStanford Cardiovascular Institute, Stanford University, Stanford, CA, USA; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Sabrina D UllmannDepartment of Chemistry, RWTH Aachen University, Aachen, Germany.
Richard H LuongDepartment of Comparative Medicine, Stanford University, Stanford, CA, USA.
Ngan F HuangStanford Cardiovascular Institute, Stanford University, Stanford, CA, USA; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA; Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA.
Sarah C HeilshornDepartment of Bioengineering, Stanford University, Stanford, CA, USA; Department of Materials Science and Engineering, Stanford University, Stanford, CA, USA; Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA. Electronic address: heilshorn@stanford.edu.
Stanford University · USVA Palo Alto Health Care System · USRWTH Aachen University · DE

Funding

Three-dimensional Scaffold-based Systems for Primary Human Intestinal CultureR01DK085720 · NIDDK · STANFORD UNIVERSITY · PI KUO, CALVIN J · 2009 to 2013
$3.7M
Engineering 3D in vitro niches to reveal fundamentals of cellular biomechanicsDP2OD006477 · OD · STANFORD UNIVERSITY · PI HEILSHORN, SARAH C · 2009 to 2009
$2.4M
Matrix-mediated endothelial differentiation of induced pluripotent stem cellsR00HL098688 · NHLBI · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI HUANG, NGAN F. · 2013 to 2016
$742k
Synergistic Molecule Delivery Using Hydrogels for BoneTissue RepairF32AR063598 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI HOLLOWAY, JULIANNE LEIGH · 2013 to 2015
$141k
NHLBI NIH HHS R00 HL098688NHLBI NIH HHS R00-HL098688NIAMS NIH HHS 5F32 AR063598NIDDK NIH HHS R01 DK085720NIH HHS DP2 OD006477NIH HHS DP2-OD006477
6 · The paper itself

Abstract

To translate recent advances in induced pluripotent stem cell biology to clinical regenerative medicine therapies, new strategies to control the co-delivery of cells and growth factors are needed. Building on our previous work designing Mixing-Induced Two-Component Hydrogels (MITCHs) from engineered proteins, here we develop protein-polyethylene glycol (PEG) hybrid hydrogels, MITCH-PEG, which form physical gels upon mixing for cell and growth factor co-delivery. MITCH-PEG is a mixture of C7, which is a linear, engineered protein containing seven repeats of the CC43 WW peptide domain (C), and 8-arm star-shaped PEG conjugated with either one or two repeats of a proline-rich peptide to each arm (P1 or P2, respectively). Both 20kDa and 40kDa star-shaped PEG variants were investigated, and all four PEG-peptide variants were able to undergo a sol-gel phase transition when mixed with the linear C7 protein at constant physiological conditions due to noncovalent hetero-dimerization between the C and P domains. Due to the dynamic nature of the C-P physical crosslinks, all four gels were observed to be reversibly shear-thinning and self-healing. The P2 variants exhibited higher storage moduli than the P1 variants, demonstrating the ability to tune the hydrogel bulk properties through a biomimetic peptide-avidity strategy. The 20kDa PEG variants exhibited slower release of encapsulated vascular endothelial growth factor (VEGF), due to a decrease in hydrogel mesh size relative to the 40kDa variants. Human induced pluripotent stem cell-derived endothelial cells (hiPSC-ECs) adopted a well-spread morphology within three-dimensional MITCH-PEG cultures, and MITCH-PEG provided significant protection from cell damage during ejection through a fine-gauge syringe needle. In a mouse hindlimb ischemia model of peripheral arterial disease, MITCH-PEG co-delivery of hiPSC-ECs and VEGF was found to reduce inflammation and promote muscle tissue regeneration compared to a saline control.

Indexed as

Tissue ScaffoldsAnimalsCells, CulturedCell ShapeChemistry, PharmaceuticalDelayed-Action PreparationsDisease Models, AnimalElastic ModulusEndothelial Progenitor CellsHindlimbHumansHydrogelsInduced Pluripotent Stem CellsInjections, IntramuscularIschemiaKineticsDelayed-Action PreparationsHydrogelsPolyethylene GlycolsRecombinant ProteinsVascular Endothelial Growth Factor AVEGFA protein, humanEndothelial cellHydrogeliPSCProtein engineeringVEGF

Identifiers

PMID24848744
PMCPMC4518026
OpenAlexW2114065822

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.